2026-01-04 - Analysis Report
Okay, let's break down this analysis of Recursion Pharmaceuticals (RXRX).

**Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to discover and develop therapeutics.

## 1. Return Rate Comparison

*   **RXRX Cumulative Return:** -31.43%
*   **VOO (S&P 500) Cumulative Return:** 39.85%
*   **Divergence:** -74.0 (Relative Divergence: 0.7)

**Analysis:** RXRX has significantly underperformed the S&P 500. A relative divergence of 0.7 indicates the current divergence is relatively low compared to its historical range.

**Alpha, Beta Analysis**

| Year      | CAGR   | MDD   | Alpha   | Beta | Cap(B) |
|-----------|--------|-------|---------|------|--------|
| 2022-2024 | 11.0%  | 55.8% | -9.0%   | 2.3  | 3.5    |
| 2023-2025 | 9.0%   | 59.2% | -53.0%  | 2.6  | 2.1    |

*   **CAGR:**  The compounded annual growth rate is around 10%, suggesting a relatively low overall average return over these periods.
*   **MDD (Maximum Drawdown):**  MDD is high, indicating significant peak-to-trough declines in value. This suggests high volatility and risk.
*   **Alpha:**  Alpha is significantly negative, especially in the 2023-2025 period.  This indicates substantial underperformance relative to the benchmark (S&P 500) after accounting for market risk.
*   **Beta:**  Beta is greater than 1 (2.3 and 2.6), meaning RXRX's price is more volatile than the overall market. It amplifies market movements.
*   **Cap(B):** This would refer to market capitalization in Billions (USD). Shows that the capitalization decreased significantly in recent times.

## 2. Recent Stock Price Fluctuations

*   **Current Close:** 4.20
*   **Last Market Data:** price: 4.2, previousClose: 4.09, change: 2.69%
*   **5-day SMA:** 4.156
*   **20-day SMA:** 4.431
*   **60-day SMA:** 4.9053

**Analysis:** The stock price is currently below all three Simple Moving Averages (SMA).  The fact that the 5-day SMA is below the 20-day SMA, which is below the 60-day SMA, suggests a short-term downtrend. The positive recent change (2.69%) from the previous close could indicate a minor rebound, but the overall trend remains downward based on the SMA data.

## 3. Indicators Analysis

*   **MRI (Market Risk Indicator):** 0.8 (Medium Investment)
*   **RSI (Relative Strength Index):** 40.10 (Suggests oversold condition, not extreme)
*   **PPO (Percentage Price Oscillator):** -0.37 (Negative, indicating a downtrend)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (228 shares - Very Safe - MRI:0.90) Monthly invest 1.7% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent (20 days) Relative Divergence Change:** 0.7 (+): 단기상승 (short-term increase)
*   **Expected Return (%):** -534.2%

**Analysis:**

*   The MRI suggests a medium level of investment risk.
*   The RSI indicates that the stock is not significantly oversold.
*   The negative PPO confirms the downtrend.
*   The Hybrid Signal recommends a full investment strategy, labeling it as "Very Safe" with a high MRI score of 0.9. This seems contradictory to the other indicators and the stock's performance, so this recommendation must be viewed with caution.
*   The recent increase in relative divergence might suggest a short-term upward movement.
*   The extremely negative expected return is highly concerning, implying very poor long-term prospects compared to the S&P 500 if investing from this point.

## 4. Recent News & Significant Events

*   **Mixed Headlines:** The news headlines present a mixed picture. Some articles discuss whether RXRX is a good penny stock investment, while others highlight JPMorgan's upgrade. Conversely, some reports mention a stock fall and others focus on a significant stock plummet. Nikko Asset Management selling shares provides more negative perspective.
*   **JPMorgan Upgrade vs. Plummet:** The conflicting news of JPMorgan's upgrade and the reported stock plummet highlights the stock's volatility and the uncertainty surrounding its future.

## 4-2. Analyst Opinions

*   **Consensus:** Negative sentiment (none specified, but indicating toward "Sell" end).
*   **Opinions:** 7
*   **Target Price:** Average target price of $7.00, with a range of $3.00 to $11.00.
* **Recent Rating Changes**: None reported

**Analysis:**  The analyst consensus, target price range, and recent ratings changes suggest a cautious or bearish outlook. The analyst coverage suggests that analysts expect significant upside, with the average target price more than 50% higher than the current price. However, the analysts are not confident in their targets, with a wide spread ($3 to $11).

## 5. Recent Earnings Analysis

| 날짜        | EPS   | 매출      |
| ----------- | ----- | --------- |
| 2025-11-05 | -0.36 | 0.01 B$   |
| 2025-08-05 | -0.41 | 0.02 B$   |
| 2025-05-05 | -0.5  | 0.01 B$   |
| 2024-11-06 | -0.34 | 0.03 B$   |
| 2025-11-05 | -0.34 | 0.03 B$   |

**Analysis:**

*   **Consistent Losses:**  The company is consistently reporting losses per share (EPS).
*   **Low Revenue:** Revenue is relatively low.
*   **Inconsistent Trend:** The revenue appears to be erratic, with no clear upward or downward trend.

## 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue    | Profit Margin |
| ---------- | ---------- | --------------- |
| 2025-09-30 | $0.00B    | -194.74%       |
| 2025-06-30 | $0.02B    | -5.54%         |
| 2025-03-31 | $0.01B    | -47.31%         |
| 2024-12-31 | $0.00B    | -183.62%       |
| 2024-09-30 | $0.03B    | 53.69%         |

**Capital and Profitability:**

| Quarter    | Equity     | ROE       |
| ---------- | ---------- | --------- |
| 2025-09-30 | $1.05B    | -15.50%   |
| 2025-06-30 | $0.92B    | -18.70%   |
| 2025-03-31 | $0.93B    | -21.68%   |
| 2024-12-31 | $1.03B    | -17.29%   |
| 2024-09-30 | $0.52B    | -18.27%   |

**Analysis:**

*   **Poor Profitability:**  Profit margins are generally very negative, indicating that the company is spending significantly more than it earns.
*   **Revenue Volatility:** Revenue is inconsistent.
*   **Negative ROE:** Return on Equity (ROE) is consistently negative, reflecting the company's inability to generate profit from shareholder equity.
*   **Equity Fluctuation:** Equity has fluctuated over the past few quarters.

## 7. Comprehensive Analysis (Summary)

Recursion Pharmaceuticals (RXRX) presents a highly risky investment opportunity. Here's a summary:

*   **Underperformance:** It has significantly underperformed the S&P 500, with a large negative divergence.
*   **High Volatility:** High MDD and beta values suggest high volatility and market sensitivity.
*   **Negative Financials:** The company is consistently unprofitable, with negative profit margins and ROE. Revenue is also volatile and has struggled to gain traction.
*   **Mixed Signals:** News headlines are mixed, reflecting the uncertainty surrounding the company's future. While some analysts see potential upside, others highlight significant risks.
*   **Concerning Indicators:** The extremely negative expected return and the negative PPO point towards continued challenges. The recommendation from the Hybrid Signal should be carefully considered in light of the other indicators and the company's overall performance.

**Conclusion:** Based on this analysis, an investment in RXRX is a high-risk, potentially high-reward proposition. It is appropriate only for investors with a high-risk tolerance and a deep understanding of the biotechnology industry. Further due diligence is highly recommended.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.